Xenotransplantation: Pig Kidney Success

The field of organ transplantation recently witnessed a historic milestone that could reshape the future of medicine. Surgeons at NYU Langone Health successfully maintained a genetically modified pig kidney in a human body for a record-breaking two months. This experiment marks the longest documented case of a gene-edited pig kidney functioning within a human, offering new hope for the thousands of patients currently languishing on organ waiting lists.

The Record-Breaking NYU Langone Experiment

In the summer of 2023, a team led by Dr. Robert Montgomery, the director of the NYU Langone Transplant Institute, initiated a study that would push the boundaries of xenotransplantation. The procedure involved transplanting a kidney from a genetically engineered pig into the body of a 58-year-old man named Maurice “Mo” Miller.

Mr. Miller had been declared brain-dead, and his family generously consented to donate his body for this critical research. The study was designed to answer a singular, vital question: Can a non-human organ survive long-term without being rejected by the human immune system?

Previous experiments had lasted only days, typically between 54 and 72 hours. This study, however, ran for 61 days. During this period, the pig kidney functioned exactly as a human kidney would. It successfully filtered toxins, including creatinine, from the blood and produced urine. Dr. Montgomery noted that the organ performed remarkably well, with biopsies taken during the study showing no signs of the rejection that typically causes such transplants to fail immediately.

The Science: The "GalSafe" Pig

The success of this procedure relied heavily on specific genetic engineering. The kidney was sourced from a “GalSafe” pig, developed by the biotech company Revivicor, a subsidiary of United Therapeutics.

Unlike other xenotransplantation experiments that utilized pigs with up to 69 genetic modifications, the NYU team took a simpler approach. They focused on a pig with just a single gene knockout. The scientists removed the gene responsible for producing “alpha-gal,” a sugar molecule found on the surface of pig cells.

Human bodies contain natural antibodies that react violently to alpha-gal. If a standard pig organ were transplanted into a human, these antibodies would detect the sugar immediately and destroy the organ within minutes, a process known as hyperacute rejection. By knocking out the gene that produces this sugar, the organ becomes effectively invisible to this immediate immune attack.

In addition to the kidney, surgeons transplanted the pig’s thymus gland. The thymus plays a role in “educating” the immune system. The medical team placed the gland under the kidney’s outer layer, theorizing that it would help the recipient’s immune cells recognize the pig organ as “friend” rather than “foe,” thereby preventing delayed rejection.

Why Two Months Matters

The duration of this study is its most significant aspect. While short-term experiments proved that the surgery was surgically possible, they could not predict how the human body would react over weeks or months. The two-month timeline allowed researchers to monitor for different types of immune responses that take time to develop.

During the 61 days, the medical team treated the recipient with standard immunosuppressive drugs, the same medication given to patients receiving human donor kidneys. The fact that the pig kidney survived using standard protocol suggests that future xenotransplants might not require exotic or highly toxic drug regimens to be successful.

The experiment was concluded in mid-September 2023, at which point the researchers removed the kidney for detailed cellular analysis. The findings confirmed that the organ remained healthy and functional until the very end of the study.

Addressing the Organ Shortage Crisis

The primary driver behind this aggressive research is the severe shortage of human organs. According to the United Network for Organ Sharing (UNOS), more than 103,000 people in the United States are currently on the waiting list for a transplant. The vast majority of these patients, nearly 89,000, are waiting for a kidney.

Tragically, 17 people die every day while waiting for an organ. Dialysis offers a stopgap measure, but it is physically taxing and not a permanent cure. Xenotransplantation offers a potential sustainable supply of organs. Pigs are considered ideal candidates for this because they reach adult size quickly (usually within six months) and their organs are anatomically similar to humans.

Ethical Considerations and The Donor

The study also sparked important conversations regarding bioethics. Using the body of a brain-dead decedent allows scientists to observe complex physiological responses that cannot be simulated in a lab dish or a computer model. This serves as a crucial bridge between animal trials and Phase 1 clinical trials in living humans.

The family of Maurice Miller viewed the donation as a legacy for their loved one. Miller’s sister, Mary Miller-Duffy, stated to the press that while her brother loved to help people, he could not donate his organs in the traditional way due to cancer. Participating in this study allowed his passing to contribute directly to saving future lives.

What Comes Next?

Following the success of the NYU Langone study, the path is now clearer for clinical trials in living patients. The FDA is currently reviewing data from this experiment, as well as similar studies conducted at the University of Alabama at Birmingham (UAB) and the University of Maryland.

While the single-gene edit used by NYU showed great promise, other institutions are testing pigs with more complex edits, including the insertion of human genes to regulate inflammation and blood clotting. The medical community is waiting to see which genetic “recipe” provides the best long-term stability.

Dr. Montgomery and his colleagues believe that within the next several years, we could see the first small-scale trials where patients with end-stage kidney disease are offered pig kidneys as a bridge to a human transplant, or potentially as a permanent solution.

Frequently Asked Questions

Is this procedure available to the public yet? No. This procedure is still in the experimental research phase. It has not yet been approved by the FDA for general medical use. The next step will be Phase 1 clinical trials involving a small number of living volunteers.

Why are pigs used instead of primates? While primates are genetically closer to humans, they pose higher risks for transmitting infections and raise significant ethical concerns regarding their use in research. Pigs are easier to raise, grow rapidly to human size, and are already widely used in agriculture, making them a more scalable source for organs.

What drugs were used to prevent rejection? The doctors used standard FDA-approved immunosuppressive medications, including mycophenolate mofetil, prednisone, and tacrolimus. These are the same drugs currently taken by patients with human kidney transplants.

Did the pig kidney function as well as a human kidney? Yes. Throughout the two-month study, the pig kidney filtered waste products like creatinine effectively and maintained fluid balance in the body, mirroring the function of a healthy human kidney.

What is the “GalSafe” pig? “GalSafe” is a trademarked line of pigs genetically engineered by Revivicor. They have been modified to lack the alpha-gal sugar molecule, which triggers severe allergic reactions and organ rejection in humans. The FDA approved GalSafe pigs for both human food consumption and potential therapeutic uses in 2020.